Company Directory - Moderna, Inc.
Company Details - Moderna, Inc.
Moderna, Inc.
WebsiteCambridge, United States
Moderna, Inc. is a commercial-stage biotechnology company known for pioneering messenger RNA (mRNA) technology. The company has gained prominence for developing therapies and vaccines, including its COVID-19 vaccine.
CCI Score
CCI Score: Moderna, Inc.
0.27
-0.01%
Latest Event
Moderna faces political scrutiny amid funding cuts
Amid intense political maneuvering and a controversial $590 million vaccine contract, Moderna finds itself entangled in partisan battles. The contract—initially approved during a sensitive transition between administrations—has become a symbol of politically charged corporate funding, raising concerns about the influence of political legacies in public health and economic decision-making.
Take Action
So what can you do? Support Moderna by shopping, spreading the word, or offering your support.
- Shop Alternatives
SEE ALL - Use Your Voice
OTHER TOOLS - Investigate
- Share the Score
SUPPORT CCI
OBJECTOR
Moderna, Inc. is currently rated as an Objector.
Latest Events
- FEB262025
Amid intense political maneuvering and a controversial $590 million vaccine contract, Moderna finds itself entangled in partisan battles. The contract—initially approved during a sensitive transition between administrations—has become a symbol of politically charged corporate funding, raising concerns about the influence of political legacies in public health and economic decision-making.
-25
Public and Political Behavior
March 27
Moderna's acceptance of a lucrative government contract under contentious political circumstances reflects its entanglement in a system where public health decisions are deeply politicized. The contract, viewed as a 'political legacy' from the previous administration, indicates a complicity in engaging with political forces that blur the lines between public service and corporate profit, thereby indirectly supporting authoritarian manipulations in policy-making.
Cracking Down on "Political Legacies"? Vaccine Pharmaceutical Companies Face Their "Darkest Hour"
-15
Economic and Structural Influence
March 27
The controversial $590 million contract, now under threat of being rescinded as part of a broader political power struggle, underscores how corporate financial arrangements can be deeply influenced by partisan dynamics. This exposes Moderna to the risks of economic and structural influence driven by political agendas, which can erode regulatory oversight and contribute to an environment where corporate profits are intertwined with authoritarian policy shifts.
Cracking Down on "Political Legacies"? Vaccine Pharmaceutical Companies Face Their "Darkest Hour"
- FEB192025
The OpenSecrets profile for Moderna Inc reveals that the company contributed $114,198 during the 2024 election cycle and spent approximately $305,000 on lobbying. In addition, the profile highlights a significant revolving door, with many lobbyists having previous government experience. These findings raise concerns about the company's influence on political processes and potential complicity in advancing authoritarian policies.
-30
Political Contributions and Lobbying Efforts
March 27
Moderna’s involvement in political financing, as evidenced by its campaign contributions and lobbying expenditures, demonstrates a concerning level of political engagement. The fact that a substantial number of its lobbyists are former government officials suggests a revolving door dynamic that may facilitate corporate influence over policy in ways that can support authoritarian practices.
- JAN012025
Moderna outlines its commitment to ethical business practices, political transparency, human rights, and responsible technology use through comprehensive ESG reporting and robust corporate policies.
+80
Public and Political Behavior
March 27
Moderna's political engagement policy emphasizes transparency by avoiding direct contributions to political campaigns, which supports resistance to authoritarian practices. This positive stance on political involvement enhances trust in their public and political behavior.
+85
Business Practices and Ethical Responsibility
March 27
The company exhibits strong ethical responsibility with clear policies on ethics, anti-bribery, modern slavery prevention, and global transparency disclosures. These measures indicate a firm commitment to human rights and ethical business practices that counter authoritarianism.
+70
Technology and Services Impact
March 27
Moderna has introduced an AI Code of Conduct and emphasizes responsible technology development, which reflects a commitment to regulating the impact of technological services and preventing misuse that could support authoritarian regimes.
- DEC312024
According to OpenSecrets, Moderna Inc. spent $305,000 on lobbying in 2024. This spending raises concerns about the company's engagement in political influence that may support authoritarian practices by prioritizing corporate interests over transparent democratic processes.
-20
Political Contributions and Lobbying Efforts
March 27
The reported $305,000 lobbying expenditure in 2024 suggests that Moderna Inc. is engaging in political activities that could be leveraged to influence policy in favor of corporate interests. This level of spending, while not extremely high compared to industry giants, is still concerning from an anti-fascist perspective as it may contribute to undermining democratic accountability and transparency.
- NOV182024
Moderna's leadership has expressed confidence in its strategic focus despite political uncertainties tied to controversial HHS nominations and potential shifts in vaccine regulatory policy. The company is also emphasizing diversification of its product pipeline to reduce reliance on politically sensitive vaccines.
+20
Public and Political Behavior
March 27
Moderna's management addressed political concerns by engaging directly with investors to discuss the potential impact of government appointments on vaccine regulation. Their proactive stance and clear messaging indicate a responsible public and political behavior, which helps mitigate risks associated with authoritarian regulatory shifts.
Moderna Remains Confident Despite Political Concerns Over Vaccine Safety and HHS Nomination
+15
Business Practices and Ethical Responsibility
March 27
The company's strategy to invest in oncology, rare diseases, and new product approvals demonstrates a commitment to long-term ethical business practices, reducing its reliance on a single politically charged product line. This diversification supports public health while insulating the company from adverse regulatory shifts.
Moderna Remains Confident Despite Political Concerns Over Vaccine Safety and HHS Nomination
- JAN012023
Moderna, Inc. outlines its comprehensive approach to corporate responsibility, including clear policies on political engagement, human rights, labor practices, anti-corruption measures, and diversity initiatives. The company’s commitment to transparency and ethical conduct demonstrates a strong stance against supporting authoritarian practices.
+70
Public and Political Behavior
October 21
Moderna’s political engagement policy explicitly states that it does not make direct contributions to political campaigns or candidates, underscoring a commitment to transparency in political activities. This proactive stance in ensuring ethical political behavior supports democratic values and counters tendencies towards authoritarian influence.
+80
Business Practices and Ethical Responsibility
October 21
Moderna’s ESG reporting highlights a robust framework for ethical business practices, including a Code of Ethics, modern slavery statement, anti-bribery/anti-corruption policy, and a CEO pledge for diversity and inclusion. These initiatives show a strong commitment to upholding human rights and ethical standards, mitigating risks of complicity in practices that may support authoritarian agendas.
- AUG082022
Moderna's August 2022 political engagement policy outlines its commitment to avoiding direct corporate contributions to political candidates and clarifies that it does not make independent political expenditures in support of or opposition to campaigns. The policy also details oversight by an independent board committee, reinforcing transparency in the company's engagements with trade associations and other politically active organizations.
+70
Political Contributions and Lobbying Efforts
March 27
Moderna’s disclosure explicitly states that it does not allocate corporate funds to political candidates, parties, or independent political expenditures. This clarity and commitment to transparency helps reduce potential corporate influence in politics and mitigates risks of bolstering authoritarian practices through covert lobbying efforts.
+65
Executive Political Engagement
March 27
The policy is further reinforced by oversight from Moderna’s independent board committee, ensuring that executive actions related to political engagement are reviewed and governed in a transparent manner. This structure helps mitigate the risk of undue executive influence in political processes, which is critical in resisting authoritarian practices.
- NOV212021
In a contentious patent dispute, Moderna refused to include key government scientists as co-inventors on its COVID-19 vaccine patent application, a decision that underscores concerns over the privatization of publicly funded research and the consolidation of market control.
-70
Business Practices and Ethical Responsibility
March 27
Moderna's decision to exclude government scientists from key patent applications represents a business practice that prioritizes private control over technology derived from significant public funding. This approach undermines public accountability and may compromise equitable access to critical health innovations, reflecting unethical behavior driven by profit over public good.
What's at Stake in the Patent Battle Between Moderna and the US Government?
-60
Economic and Structural Influence
March 27
By retaining exclusive control over its vaccine patents despite heavy public funding, Moderna is consolidating market power and undermining potential governmental leverage to ensure fair pricing and equitable distribution. This action reflects broader economic and structural issues where corporate control over public resources may enable practices detrimental to democratic oversight.
What's at Stake in the Patent Battle Between Moderna and the US Government?
- NOV122021
In November 2021, Moderna defended its patent claims over its COVID-19 vaccine amid escalating tensions with U.S. government officials who demanded that NIH scientists be credited as co-inventors. The company's stance, coming despite nearly $10 billion in government funding, raised concerns about its commitment to public accountability and equitable access.
- NOV012021
Moderna’s refusal to share key patent rights with the U.S. government despite significant public funding has raised concerns over its commitment to public accountability and equitable access in vaccine distribution.
Alternatives
Menlo Park, United States
-49.80
Thousand Oaks, USA
13.63
Corporation
0.00
Corporation
-45.47
_0.png?VersionId=E54j6B2ssY0mos4wxJcXCOh7Hall1IAR)
New York, United States
-1.65
Cranbury, United States
-15.14
San Carlos, United States
-24.95
The Woodlands, United States
-29.63
Indianapolis, United States
-35.34
Seattle, United States
-38.14
Industries
- 325412
- Pharmaceutical Preparation Manufacturing
- 541715
- Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- 621511
- Medical Laboratories